Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges.

In recent years, AIDS and sexually transmitted diseases (STDs) have become a burgeoning problem and are spreading at an alarming rate. Microbicides are being developed as a new therapeutic category for prevention of transmission of sexually transmitted infections (STIs) and HIV. Many of the microbic...

Descripción completa

Detalles Bibliográficos
Publicado en:AIDS Patient Care & STDs Vol. 17; no. 8; pp. 377 - 400
Autores principales: Garg S, Tambwekar KR, Vermani K, Kandarapu R, Garg A, Waller DP, Zaneveld LJD
Formato: review tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Aug2003
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106726263&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106726263
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10872914
        33C
      jtl: AIDS Patient Care & STDs
      issn: 10872914
      maglogo: N
    pubinfo:
      dt: Aug2003
      vid: 17
      iid: 8
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        106726263
        106726263
        2004059164
        10.1089/108729103322277402
        NLM13678540
        106726263
      ppf: 377
      ppct: 23
      formats:
      tig:
        atl: Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges.
      aug:
        au:
          Garg S
          Tambwekar KR
          Vermani K
          Kandarapu R
          Garg A
          Waller DP
          Zaneveld LJD
        affil: Dept of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar, Punjab 160062, India; gargsanjay@yahoo.com
      sug:
        subj:
          Administration, Intravaginal
          Antiinfective Agents Administration and Dosage
          Chemistry, Pharmaceutical
          Dosage Forms
          Product Development
          Sexually Transmitted Diseases Prevention and Control
          Administration, Rectal
          Antiinfective Agents Pharmacodynamics
          Antiinfective Agents Pharmacokinetics
          Creams
          Drug Packaging
          Drug Stability
          Drug Storage
          Emulsions
          Funding Source
          Gels
          HIV Infections
          Ointments
          Pessaries
          Product Evaluation
          Solubility
          Suppositories
          Suspensions
          Tablets
      ab: In recent years, AIDS and sexually transmitted diseases (STDs) have become a burgeoning problem and are spreading at an alarming rate. Microbicides are being developed as a new therapeutic category for prevention of transmission of sexually transmitted infections (STIs) and HIV. Many of the microbicide formulations (MF) may fail to elicit a protective response either because of a lack of efficacy or inadequate formulation. Manufacturing a stable, efficacious, safe, and optimal product is the main objective of formulation development programs. Preformulation parameters (PP), as discussed in Part I of this series, influence formulation development significantly and should be considered carefully before designing a formulation strategy. Initially, based on PP and market research, a target product profile (TPP) is generated, which defines product attributes that can be normally classified as 'essential' and 'desirable.' A complex and dynamic process begins thereafter that takes into consideration myriad factors starting from selection of delivery system, selection of excipients, compatibility study, prototype composition, selection of process and optimization, stability testing, scale up, manufacturing under good manufacturing practices (GMP), and packaging development. Prototype formulations are evaluated for several performance characteristics (e.g., dispersion behavior, bioadhesion, retention, spreading, rheology). These compositions are also subjected to biologic evaluation by various in vitro and in vivo models. Such a well-planned, well-coordinated, and well-implemented formulation development program not only accelerates overall development but also minimizes failures in subsequent clinical development studies. The objective of this review is to highlight the importance of formulation science, outline the steps involved in this process, and explore how these can be exploited for achieving optimal MF.
      pubtype: Academic Journal
      doctype:
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N